Research programme: peptides - Biolingus

Drug Profile

Research programme: peptides - Biolingus

Alternative Names: Project B2 (OPUS/SLIT) - Biolingus; Project B3 (OPUS) - Biolingus; Project B5 (SLIT) - Biolingus

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biolingus
  • Class Antihyperlipidaemics; Antineoplastics; Antirheumatics; Biobetters; Dendritic cell vaccines; Peptides
  • Mechanism of Action Immunostimulants; PCSK9 protein inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Hypercholesterolaemia; Rheumatoid arthritis

Most Recent Events

  • 19 Sep 2017 The peptides are available for licensing as of 19 Sep 2017. http://www.biolingus.ch/products_1.html
  • 19 Sep 2017 Preclinical trials in Cancer in Switzerland (Sublingual) before September 2017 (Biolingus pipeline, September 2017)
  • 19 Sep 2017 Preclinical trials in Hypercholesterolaemia in Switzerland (Sublingual) before September 2017 (Biolingus pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top